Double‐Blind Placebo‐Controlled Trial of Bepotastine Salicylate in Patients With Allergic Rhinitis
- 31 July 2020
- journal article
- research article
- Published by Wiley in The Laryngoscope
- Vol. 131 (3) , E702-E709
Abstract
Objectives/Hypothesis: To evaluate the efficacy and safety of a slow‐release form of bepotastine salicylate (HL151, Belion CR) in patients with perennial allergic rhinitis (PAR).Study Design: Double‐blind, placebo‐controlled multicenter comparative study.Methods: Two hundred seventy‐two PAR patients (aged 19–65 years) were studied to determine the efficacy and safety of HL151 (20 mg once daily administration) relative to those of a placebo in terms of improvements in total and nasal symptom scores. The subjects were randomized to the placebo (n = 138) or HL151 group (n = 134, 20 mg orally once daily for 4 weeks), and reflective and instantaneous total nasal symptom scores (TNSS) were measured daily in comparison with baseline. Among 272 subjects, 229 subjects (119 in the placebo group, 110 in the HL151 group) who completed the study were included for efficacy analysis.Results: Instantaneous and reflective TNSS and nasal symptoms such as rhinorrhea, nasal itching, and sneezing at 2 and 4 weeks showed that HL151 was superior to the placebo (all P < .05). There were no significant differences in terms of adverse events and adverse drug reactions between the two groups. Regarding serious adverse events, there was only one case of acute hepatitis B, which was reported not to be associated with HL151.Conclusions: This multicenter trial showed that once‐daily use of HL151 is efficacious and safe in adult patients with PAR and could improve compliance due to its convenience.Level of Evidence: 1b Laryngoscope, 131:E702–E709, 2021Keywords
This publication has 16 references indexed in Scilit:
- Pharmacokinetic Comparisons of Bepotastine Besilate and Bepotastine Salicylate in Healthy SubjectsClinical Drug Investigation, 2013
- Development of novel bepotastine salicylate salt bioequivalent to the commercial bepotastine besilate in beagle dogsDrug Development and Industrial Pharmacy, 2012
- A Comparative Analysis of the Impact of a Positive List System on New Chemical Entity Drugs and Incrementally Modified Drugs in South KoreaClinical Therapeutics, 2011
- Non-clinical pharmacology, pharmacokinetics, and safety findings for the antihistamine bepotastine besilateCurrent Medical Research and Opinion, 2010
- Bepotastine besilate, a highly selective histamine H1 receptor antagonist, suppresses vascular hyperpermeability and eosinophil recruitment in in vitro and in vivo experimental allergic conjunctivitis modelsExperimental Eye Research, 2010
- Bepotastine besilate OD tablets suppress nasal symptoms caused by Japanese cedar pollen exposure in an artificial exposure chamber (OHIO Chamber)Expert Opinion on Pharmacotherapy, 2009
- Brain histamine H1receptor occupancy of orally administered antihistamines, bepotastine and diphenhydramine, measured by PET with11C‐doxepinBritish Journal of Clinical Pharmacology, 2008
- Effects of bepotastine, cetirizine, fexofenadine, and olopatadine on histamine-induced wheal-and flare-response, sedation, and psychomotor performanceClinical and Experimental Dermatology, 2004
- Efficacy and Tolerability Comparison of Ebastine 10 and 20mg with Loratadine 10mgClinical Drug Investigation, 1998
- A Novel Anti-Allergic Drug, Betotastine Besilate, Suppresses Interleukin-5 Production by Human Peripheral Blood Mononuclear Cells.Biological and Pharmaceutical Bulletin, 1998